Person who experienced the adverse event (patient)
Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
125490253 | 12549025 | 3 | F | 20160207 | 20160928 | 20160712 | 20160929 | EXP | US-PFIZER INC-3198717 | PFIZER | 52.00 | YR | M | Y | 145.00000 | KG | 20160929 | OT | US | US |
Drug(s) used by person
Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
125490253 | 12549025 | 1 | SS | EPOGEN | ERYTHROPOIETIN | 1 | Intravenous (not otherwise specified) | 8200 IU, UNK | UNK | 0 | 8200 | IU | |||||||
125490253 | 12549025 | 2 | SS | EPOGEN | ERYTHROPOIETIN | 1 | Intravenous (not otherwise specified) | 5200 IU, UNK | UNK | 0 | 5200 | IU | |||||||
125490253 | 12549025 | 3 | PS | ALPRAZOLAM. | ALPRAZOLAM | 1 | Oral | 2 MG, AS NEEDED | Y | 18276 | 2 | MG | |||||||
125490253 | 12549025 | 4 | SS | HYDROMORPHONE HYDROCHLORIDE. | HYDROMORPHONE HYDROCHLORIDE | 1 | Intravenous (not otherwise specified) | 1 MG, AS NEEDED, EVERY 4 HOURS | Y | 74598 | 1 | MG | |||||||
125490253 | 12549025 | 5 | SS | MORPHINE SULFATE. | MORPHINE SULFATE | 1 | Intravenous (not otherwise specified) | 2 MG, AS NEEDED | Y | 19999 | 2 | MG | |||||||
125490253 | 12549025 | 6 | SS | HYDROCODONE BITARTRATE AND ACETAMINOPHEN | ACETAMINOPHENHYDROCODONE BITARTRATE | 1 | Oral | 10 MG/325 MG, ONCE | D | 0 | 1 | DF | |||||||
125490253 | 12549025 | 7 | SS | TRAMADOL. | TRAMADOL | 1 | Oral | 50 MG, AS NEEDED | 0 | 50 | MG | ||||||||
125490253 | 12549025 | 8 | SS | ATIVAN | LORAZEPAM | 1 | Intravenous (not otherwise specified) | 1 MG, 2 DOSES | 0 | 1 | MG | ||||||||
125490253 | 12549025 | 9 | SS | HALOPERIDOL LACTATE. | HALOPERIDOL LACTATE | 1 | Intravenous (not otherwise specified) | 5 MG, ONCE | Y | 0 | 5 | MG | |||||||
125490253 | 12549025 | 10 | SS | HALOPERIDOL LACTATE. | HALOPERIDOL LACTATE | 1 | Intravenous (not otherwise specified) | 10 MG, ONCE | Y | 0 | 10 | MG | |||||||
125490253 | 12549025 | 11 | C | IRON | IRON | 1 | UNK | UNK | 0 |
Indications of drugs used
Event ID | CASEID | INDI DRUG SEQ | INDI PT |
---|---|---|---|
125490253 | 12549025 | 1 | Nephrogenic anaemia |
125490253 | 12549025 | 3 | Agitation |
125490253 | 12549025 | 4 | Arthralgia |
125490253 | 12549025 | 5 | Arthralgia |
125490253 | 12549025 | 6 | Arthralgia |
125490253 | 12549025 | 7 | Arthralgia |
125490253 | 12549025 | 8 | Agitation |
125490253 | 12549025 | 9 | Agitation |
125490253 | 12549025 | 11 | Nephrogenic anaemia |
Outcome of event
Event ID | CASEID | OUTC COD |
---|---|---|
125490253 | 12549025 | LT |
125490253 | 12549025 | HO |
Reactions reported
Event ID | CASEID | DRUG REC ACT | PT |
---|---|---|---|
125490253 | 12549025 | Osteomyelitis | |
125490253 | 12549025 | Respiratory arrest | |
125490253 | 12549025 | Tibia fracture |
Reporting Sources (this data is often not reported and may therefore be missing here)
no results found |
Therapies reported
Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
---|---|---|---|---|---|---|
125490253 | 12549025 | 1 | 20151218 | 0 | ||
125490253 | 12549025 | 2 | 20151226 | 0 | ||
125490253 | 12549025 | 3 | 20160207 | 20160209 | 0 | |
125490253 | 12549025 | 4 | 20160207 | 20160210 | 0 | |
125490253 | 12549025 | 5 | 20160207 | 20160209 | 0 | |
125490253 | 12549025 | 6 | 20160207 | 20160207 | 0 | |
125490253 | 12549025 | 7 | 20160208 | 20160208 | 0 | |
125490253 | 12549025 | 8 | 20160210 | 20160210 | 0 | |
125490253 | 12549025 | 9 | 20160210 | 20160210 | 0 | |
125490253 | 12549025 | 10 | 20160210 | 20160210 | 0 |